Table 3.
Results from multivariable Cox regression stratified by study cohort and HF subtype
| Variables | Transformation | Coef (SE) | HR (95% CI) | Pinteraction |
|---|---|---|---|---|
| Age, year | 0.023 (0.004) | 1.02 (1.02–1.03) | ||
| COPD | 0.298 (0.087) | 1.35 (1.14–1.60) | ||
| NYHA class III | 0.360 (0.124) | 1.43 (1.12–1.83) | ||
| NYHA class IV | 0.298 (0.133) | 1.35 (1.04–1.75) | ||
| Hemoglobin, mmol/L | − 0.164 (0.034) | 0.85 (0.79–0.91) | ||
| Sodium, mmol/L | − 0.032 (0.009) | 0.97 (0.95–0.99) | ||
| BUN, mmol/L | = log2(x*) | 0.335 (0.065) | 1.40 (1.23–1.59) | |
| NT-proBNP, ng/L | = log2(x) | 0.294 (0.035) | 1.34 (1.25–1.44) | |
| SBP (HFrEF), mmHg | = min(x,130)† | − 0.029 (0.003) | 0.97 (0.96–0.98) | < .001 |
| SBP (HFmrEF), mmHg | = min(x,130) | − 0.009 (0.008) | 0.99 (0.98–1.01) | |
| SBP (HFpEF), mmHg | = min(x,130) | − 0.006 (0.007) | 0.99 (0.98–1.01) | |
| Creatinine (HFrEF), μmol/L | = log2(x) | 0.037 (0.100) | 1.04 (0.85–1.26) | .010 |
| Creatinine (HFmrEF), μmol/L | = log2(x) | − 0.367 (0.140) | 0.69 (0.53–0.91) | |
| Creatinine (HFpEF), μmol/L | = log2(x) | − 0.209 (0.150) | 0.81 (0.54–1.19) | |
| MI (HFrEF) | 0.430 (0.097) | 1.54 (1.27–1.86) | .001 | |
| MI (HFmrEF) | − 0.032 (0.188) | 0.97 (0.67–1.40) | ||
| MI (HFpEF) | − 0.216 (0.201) | 0.79 (0.53–1.17) | ||
| Diabetes (HFrEF) | 0.265 (0.101) | 1.30 (1.07–1.59) | .041 | |
| Diabetes (HFmrEF) | − 0.176 (0.202) | 0.84 (0.56–1.25) | ||
| Diabetes (HFpEF) | − 0.077 (0.190) | 0.93 (0.64–1.34) |
*x stands for original value
†The SBP has a linear trend up to 130 mmHg, while above 130 mmHg the risk is constant. Therefore, we truncated SBP at 130 mmHg